Bluejay Diagnostics, Inc. - BJDX STOCK NEWS

Bluejay Diagnostics (NASDAQ: BJDX) has announced the closing of its $8.75 million underwritten public offering, completed on June 28, 2024.

This offering included 5,368,098 Common Units or Prefunded Units, each priced at $1.63 and $1.6299 respectively. The proceeds will be used to repay $2.3 million in outstanding debt and to fund FDA approval processes and general working capital needs.

This offering includes several warrant types, such as Class C and Class D Warrants, which have specific exercise prices and expiration terms. Aegis Capital Corp. acted as the underwriter, and the offering was made under SEC registration statement Form S-1.

Bluejay Diagnostics (NASDAQ: BJDX) announced the pricing of an $8.75 million underwritten public offering. The offering includes 5,368,098 Common Units or Prefunded Units, each with one share of common stock or one pre-funded warrant and three types of warrants for additional stock purchases. The company set the purchase price for Common Units at $1.63 and Prefunded Units at $1.6299. Proceeds will be used to repay $2.3 million of outstanding debt, fund FDA approval-related activities, and support R&D and working capital. The offering is expected to close on June 28, 2024, with Aegis Capital Corp. as the underwriter.

Bluejay Diagnostics announced the primary results of their SYMON-I pilot clinical study, which suggests that interleukin-6 (IL-6) can predict mortality in sepsis and septic shock patients within 28 days of ICU admission. The study compared IL-6 levels to standard clinical tests like lactate and SOFA, finding IL-6 to be a more reliable predictor of mortality. The results will be validated in the SYMON-II study set to begin in Q3 2024. Positive results from SYMON-II could support a 510(k) application to the FDA in 2025. The company aims to present these results at scientific meetings and publish them in peer-reviewed journals, contingent on raising additional capital.

Bluejay Diagnostics announced a 1-for-8 reverse stock split effective June 20, 2024. This will reduce outstanding shares from approximately 4.5 million to around 564,000, with no change in par value. Fractional shares will be compensated in cash. The stock will trade under the same symbol, BJDX, but with a new CUSIP number. The reverse split affects all shareholders uniformly, preserving their percentage ownership except for fractional share adjustments. The transfer agent for this process is Continental Stock Transfer & Trust Company. Bluejay focuses on rapid diagnostics to improve patient outcomes in critical care settings.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the closing of a public offering of 2,692,308 shares of common stock and warrants, generating approximately $3.5 million in gross proceeds. The company intends to use the net proceeds for obtaining FDA approval, clinical studies, research and development, and general working capital needs.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the pricing of a public offering of 2,692,308 shares of common stock and warrants to purchase up to 2,692,308 shares at a combined offering price of $1.30 per share. The offering is expected to close on December 28, 2023.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announces the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients, positioning the company to move forward with multiple initiatives.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported its financial results for the quarter and nine months ended September 30, 2023. The company focused on implementing a modified clinical strategy based on FDA feedback and plans to submit for regulatory approval for Symphony IL-6 in the first half of 2024. Bluejay renegotiated its licensing and supply agreements with Toray Industries, Inc., reducing royalty payments and securing critical component supply for the Symphony Cartridge. Symphony IL-6 testing has the potential to improve outcomes for sepsis patients by enabling healthcare providers to better prioritize care. Cash and cash equivalents on September 30, 2023, were $5.08 million, with an estimated sufficient fund to operate into the first quarter of 2024. The company expects to seek additional capital through various means for its planned operations.

Bluejay Diagnostics, Inc. announces purchase and sale of 216,000 shares of common stock in a registered direct offering and concurrent private placement. Gross proceeds expected to be approximately $1.59 million. Net proceeds to be used for FDA approval, research and development, and working capital.